The companies shaping life science tools are competing on far more than laboratory instruments. The real competitive battle is increasingly centered on who owns the scientific workflow.
From sample preparation and sequencing to mass spectrometry, cell analysis, proteomics, bioprocessing, laboratory automation, reagents, consumables and software, leading companies are expanding across multiple stages of research and biopharmaceutical development.
The industry’s competitive structure is led by a mix of diversified giants and highly specialized technology companies.
Download Sample https://www.precedenceresearch.com/sample/1064
Key names include:
- Thermo Fisher Scientific
- Danaher
- Agilent Technologies
- Illumina
- Bio-Rad Laboratories
- Bruker
- Bio-Techne
- Revvity
- Waters Corporation
- QIAGEN
Who Has the Broadest Competitive Reach?
| Company | Major Strength | Competitive Position |
|---|---|---|
| Thermo Fisher Scientific | End-to-end laboratory and biopharma capabilities | Scale leader |
| Danaher | Portfolio of specialized scientific platforms | Multi-brand ecosystem |
| Agilent | Analytical instruments and laboratory workflow | Analytical science leader |
| Illumina | Sequencing | Genomics specialist |
| Bio-Rad | Research instruments and reagents | Core life science workflows |
| Bruker | Advanced scientific instruments | High-end analytical technologies |
| Bio-Techne | Proteins, reagents and spatial biology | High-growth specialized tools |
| Revvity | Imaging, diagnostics and research technologies | Integrated life science platform |
| Waters | Chromatography and mass spectrometry | Analytical workflow specialist |
| QIAGEN | Sample-to-insight technologies | Molecular testing and research workflows |
The companies with the strongest positions are increasingly trying to increase the amount of laboratory workflow they control.
Sample → Preparation → Analysis → Data → Interpretation
That is becoming a major competitive strategy.
Why Is Thermo Fisher Scientific the Scale Leader?
Thermo Fisher Scientific operates one of the broadest portfolios across scientific instruments, laboratory products, consumables and biopharma services.
The company’s 2025 revenue reached US$44.56 billion, compared with US$42.88 billion in 2024. Its largest business segment, Laboratory Products and Biopharma Services, generated US$23.98 billion, while Life Sciences Solutions generated US$10.37 billion and Analytical Instruments generated US$7.55 billion.
Its competitive ecosystem spans:
- Laboratory consumables
- Reagents
- Analytical instruments
- Mass spectrometry
- Genetic analysis
- Cell biology
- Protein biology
- Bioprocessing
- Pharmaceutical and biotechnology services
Company insight
Thermo Fisher’s biggest advantage is portfolio depth.
A customer can potentially purchase instruments, consumables, reagents and services from the same company across multiple stages of scientific and biopharmaceutical workflows.
That creates strong cross-selling opportunities and recurring consumables revenue.
How Does Danaher Build Its Competitive Advantage?
Danaher has built its scientific portfolio largely through a combination of acquisitions, operating discipline and specialized businesses.
In 2025, Danaher’s Life Sciences segment generated approximately US$7.33 billion in sales, while its Biotechnology segment generated approximately US$7.29 billion. Total company sales reached approximately US$24.57 billion.
Danaher’s portfolio includes businesses and technologies associated with:
- Beckman Coulter Life Sciences
- Cytiva
- Leica Microsystems
- Molecular Devices
- SCIEX
- Integrated DNA Technologies
- Aldevron
- Abcam
Its Life Sciences business spans instruments, consumables, automation, mass spectrometry, microscopy and other scientific workflows.
Notably, 66% of Danaher’s 2025 Life Sciences sales were recurring, highlighting the importance of consumables and repeat purchases.
Company insight
Danaher’s strategy is not based on building one dominant product.
It is building an ecosystem of specialized scientific businesses.
Its acquisition history—including Leica Microsystems, Beckman Coulter, Pall, Phenomenex, IDT, Aldevron and Abcam—shows how the company has steadily expanded its technological footprint.
What Makes Agilent a Major Analytical Science Company?
Agilent Technologies has a particularly strong position in analytical workflows.
Its technologies include:
- Liquid chromatography
- Gas chromatography
- Mass spectrometry
- Spectroscopy
- Cell analysis
- Pathology
- Laboratory informatics
- Companion diagnostics
- Laboratory services
Agilent reported US$6.95 billion in revenue for fiscal 2025, up 7% from fiscal 2024. Its Life Sciences and Diagnostics segment generated US$2.73 billion, representing 11% growth from the previous year.
Agilent’s CrossLab segment generated US$2.91 billion, demonstrating the importance of services, consumables and laboratory support alongside instrument sales.
Company insight
Agilent’s model benefits from the installed base.
Once an analytical instrument is operating inside a laboratory, it can generate continuing demand for:
Columns + consumables + maintenance + software + laboratory services
That recurring relationship is strategically valuable.
Who Dominates the Sequencing Revolution?
Illumina
Illumina remains one of the most important companies in next-generation sequencing.
Its competitive position is centered on technologies used across:
- Whole-genome sequencing
- Clinical research
- Oncology research
- Rare disease research
- Population genomics
- Pharmaceutical research
Illumina’s core strategic challenge is different from that of diversified competitors.
Rather than owning every laboratory workflow, the company must continue defending and expanding its position in genomic sequencing while competition increases across the genomics ecosystem.
Company insight
Illumina’s competitive strength comes from technological specialization and its extensive installed base.
Its long-term success depends heavily on maintaining innovation in sequencing performance, throughput, cost and workflow simplicity.
Why Is Bio-Rad Important Across Core Research Workflows?
Bio-Rad Laboratories operates across both Life Science and Clinical Diagnostics.
The company generated approximately US$2.58 billion in total sales in 2025.
Its Life Science segment generated approximately US$1.02 billion, while Clinical Diagnostics contributed approximately US$1.56 billion.
Bio-Rad’s Life Science portfolio includes:
- Instruments
- Systems
- Reagents
- Consumables
- Cell analysis
- Protein analysis
- Nucleic acid technologies
The company has direct operations in more than 36 countries outside the United States, while approximately 60% of its 2025 sales came from international locations.
Company insight
Bio-Rad benefits from a broad scientific customer base.
Its products are used across:
Academic research + biotechnology + pharmaceutical development + manufacturing + quality control + food testing
That diversity provides exposure to multiple research and applied science environments.
How Does Bruker Compete Through Advanced Instrumentation?
Bruker has built its competitive position around high-performance scientific instruments.
Its technologies include:
- Mass spectrometry
- Nuclear magnetic resonance
- Cellular analysis
- Microbiology
- Spatial biology
- Proteomics
- Advanced imaging
Bruker’s strategy is particularly important in high-complexity scientific applications where performance and technological differentiation matter more than simple instrument volume.
Company insight
Bruker competes where scientific complexity is high.
Its advantage is closely connected to research areas that demand increasingly sophisticated measurement and analysis technologies.
What Is Driving Bio-Techne’s Specialized Growth Strategy?
Bio-Techne has developed a strong position in specialized biological tools.
Its portfolio includes technologies related to:
- Proteins
- Antibodies
- Reagents
- Cell and gene therapy
- Proteomics
- Spatial biology
- Genomics
Bio-Techne is an example of a company competing through specialized, high-value biological content rather than broad laboratory infrastructure.
Company insight
The strategic value of specialized reagents can be significant.
A laboratory may change general equipment suppliers, but validated biological reagents integrated into established research workflows can create stronger customer retention.
Where Is Revvity Expanding Its Scientific Footprint?
Revvity has positioned itself across life science technologies, diagnostics and laboratory workflows.
Its capabilities include:
- Cellular imaging
- Detection technologies
- Research reagents
- Informatics
- Automation
- Screening
Company insight
Revvity’s strategic opportunity lies in connecting instruments and biological research with software and data.
As laboratories generate larger volumes of experimental data, the value of integrated informatics is increasing.
Why Is Waters Still a Critical Analytical Technology Company?
Waters Corporation has long maintained a strong position in:
- Liquid chromatography
- Mass spectrometry
- Laboratory informatics
- Analytical workflows
Its technologies are deeply embedded in pharmaceutical research, development and quality control.
Company insight
Waters demonstrates the strength of specialization.
Rather than competing across every scientific discipline, it has built strong expertise around analytical chemistry workflows.
This can create long customer relationships because analytical instruments are often embedded in validated laboratory processes.
How Does QIAGEN Build a Sample-to-Insight Strategy?
QIAGEN focuses heavily on molecular biology workflows.
Its portfolio covers:
- Sample preparation
- Molecular testing
- PCR technologies
- Genomics
- Bioinformatics
- Research reagents
Company insight
QIAGEN’s strategy is centered on controlling more of the workflow from the biological sample to the scientific result.
Sample → Preparation → Molecular Analysis → Data Interpretation
This workflow-oriented approach is increasingly important as customers look to simplify laboratory processes.
What Is the Biggest Competitive Difference Between the Leading Companies?
| Company | Primary Competitive Strength |
|---|---|
| Thermo Fisher Scientific | Portfolio breadth and global scale |
| Danaher | Specialized brands and acquisition-driven expansion |
| Agilent | Analytical workflows and recurring laboratory services |
| Illumina | Genomic sequencing specialization |
| Bio-Rad | Broad research tools and reagents |
| Bruker | Advanced scientific instrumentation |
| Bio-Techne | Specialized biological reagents and spatial biology |
| Revvity | Research technologies combined with informatics |
| Waters | Analytical chemistry specialization |
| QIAGEN | Integrated molecular workflows |
The largest difference is how each company approaches the laboratory customer.
Some want to own the entire workflow.
Others want to dominate one highly specialized technology.
How Are Acquisitions Reshaping Company Strategies?
Acquisitions remain one of the most important ways companies expand their scientific capabilities.
Danaher’s historical expansion provides one of the clearest examples. The company has added technologies and businesses through acquisitions including:
- Leica Microsystems
- Beckman Coulter
- Pall
- Phenomenex
- IDT
- Aldevron
- Abcam
These acquisitions expanded Danaher’s capabilities across imaging, automation, filtration, genomics, bioprocessing and biological reagents.
Agilent’s acquisition of BIOVECTRA also contributed approximately 2 percentage points to its 2025 revenue growth, demonstrating how acquisitions can immediately add new capabilities and revenue streams.
Company insight
The acquisition strategy is evolving beyond simply adding revenue.
Companies are increasingly buying:
Technology + Scientific Expertise + Customer Relationships + Specialized Consumables
Who Benefits Most From Recurring Revenue?
One of the most attractive business models in this industry is the combination of:
Instrument + Consumables + Service + Software
The instrument creates the installed base.
The installed base generates future demand.
Danaher’s 2025 Life Sciences segment derived 66% of its sales from recurring revenue, illustrating the importance of consumables and repeat purchasing in company economics.
Agilent’s CrossLab business, with approximately US$2.91 billion in fiscal 2025 revenue, similarly demonstrates the value of building services and consumables around laboratory infrastructure.
Company insight
The strongest companies are not necessarily those that sell the most instruments once.
They are often the companies that continue generating revenue after the instrument is installed.
What Technologies Are Creating the Strongest Competitive Opportunities?
Genomics
Companies such as Illumina and QIAGEN are positioned around expanding molecular analysis and genomic workflows.
Proteomics
Thermo Fisher, Bruker, Bio-Techne and other specialized companies are expanding capabilities across protein analysis.
Spatial Biology
Advanced imaging and biological analysis are creating opportunities for companies that combine scientific instruments with biological reagents and software.
Laboratory Automation
Automation is becoming increasingly important as laboratories seek higher throughput, reproducibility and efficiency.
Bioprocessing
Danaher and Thermo Fisher have substantial positions in technologies supporting biologics, cell therapy, gene therapy and other advanced therapeutic development.
AI and Scientific Data
The next competitive frontier may involve connecting laboratory instruments with software, informatics and AI-driven analysis.
Buy This Report https://www.precedenceresearch.com/checkout/1064
About Us
Healthcare Prism is a dedicated healthcare insights and outreach platform, operating as an extension of Precedence Research. We share relevant perspectives, industry developments, emerging trends, and research-driven insights across the global healthcare sector. Our content is built on the knowledge, research standards, and expertise of Precedence Research, with a focus on making healthcare information clear, accessible, and useful for industry professionals, businesses, researchers, and healthcare stakeholders. Healthcare Prism serves as a focused platform to extend the reach of Precedence Research’s healthcare insights and connect them with a broader professional audience.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Quick Contact:
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04 and +65 31065601
Visit Our Website: https://www.precedenceresearch.com